<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175004</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 420915-CS3</org_study_id>
    <nct_id>NCT02175004</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)</brief_title>
  <official_title>An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in
      patients with Familial Amyloid Polyneuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial Amyloid Polyneuropathy (FAP) is a rare, hereditary disease caused by mutations in
      the transthyretin (TTR) protein. TTR is made by the liver and secreted into the blood. TTR
      mutations cause it to misfold and deposit in multiple organs causing FAP.

      IONIS-TTR Rx is an antisense drug that is designed to decrease the amount of mutant and
      normal TTR made by the liver. It is predicted that decreasing the amount of TTR protein will
      result in a decrease in the formation of TTR deposits, and thus slow or stop disease
      progression.

      This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in
      patients with Familial Amyloid Polyneuropathy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types of adverse events that occur during treatment</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in blood pressure (systolic and diastolic), heart rate, and body weight</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in results of routine laboratory test panel (routine serum chemistry, hematology, and urinalysis)</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in QTcF determined from electrocardiogram measurements</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in number of concomitant medications used</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in visual acuity measured during ophthalmic exam</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in light detection ability measured by electroretinography</measure>
    <time_frame>Week 52 of Year 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the modified Neuropathy Impairment Score +7</measure>
    <time_frame>78 and 156 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Neuropathy Impairment Score</measure>
    <time_frame>Week 52 of Years 4 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Norfolk Quality of Life Diabetic Neuropathy Questionnaire</measure>
    <time_frame>Week 78, 156 and Week 52 of Years 4 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Modified body mass index (mBMI) and body mass index (BMI)</measure>
    <time_frame>78 and 156 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Polyneuropathy disability score (PND)</measure>
    <time_frame>Week 78, 156 and Week 52 of Years 4 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in Transthyretin (TTR) and Retinol Binding Protein 4 (RBP4)</measure>
    <time_frame>Week 78, 156 and Week 52 of Years 4 and 5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>FAP</condition>
  <condition>Familial Amyloid Polyneuropathy</condition>
  <condition>TTR</condition>
  <condition>Transthyretin</condition>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>IONIS-TTR Rx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-TTR Rx</intervention_name>
    <description>300 mg IONIS-TTR Rx administered once weekly</description>
    <arm_group_label>IONIS-TTR Rx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Satisfactory completion of dosing &amp; efficacy assessments in ISIS 420915-CS2

        Exclusion Criteria:

          -  Any new condition or worsening of existing condition that could make the patient
             unsuitable for participation, or interfere with the patient participating in and/or
             completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine - Amyloid Treatment &amp; Research Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - The Neurological Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FLENI</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro - University Hospital</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>CEP 21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AACD</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - Department of Neurology</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Messina - Azienda Ospedaliera Universitaria Policlinico &quot;Gaetano Martino&quot;</name>
      <address>
        <city>Messina</city>
        <state>Sicily</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLN - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP-HGSA, Unidade Clinica de Paramiloidose</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London - National Amyloidosis Centre</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FAP</keyword>
  <keyword>Familial Amyloid Polyneuropathy</keyword>
  <keyword>TTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

